Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
15. Borba EF, Bonf E. Longterm beneficial effect of chloroquine diphosphonate on lipoprotein profile in lupus patients with and without steroid therapy. JRheumatology 2001; 28: 780—785.
16. Powrie JK, Shojaee-Maradie F, Watts GF, et al. Effects of chloroquine on the dyslipidemia of non-insuline-dependent diabetes mellitus. Metabolism 1993; 42: 415—419.
17. Petri M, Lakata C, Madger L, Goldman D. Effect of prednisolon and hyroxychloroquine on coronary artery risk factors in systemic lupus ery-thematosus: a longitudinal data analysis. Am J Med 1994; 96: 254—259.
18. Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322—326.
19. Hodis NH, Quismorio FP, Wickham E. et al. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661—665.
20. Kavanaugh A, Adams-Huet B, Jain R, et al. Hydroxychloroquine effect on lipoprotein profiles (HELP trial): a double-blind, randomized placebo-controlled pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997; 3:3—8.
21. Rahman P, Gladman DD, Urowitz MB, et al. The cholesterol lowering effect od antimalarial drugs is enhanced in patients with lupus taking cortocosteroid drugs. JRheumatol 199; 26: 325— 330.
22. Tam LS, Li EK, Lam CW, Tomlison B. Hydroxychloroquine has no significant effect on
lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 2000; 9: 413—416.
23. Tam LS, Gladman DD, Hallett D, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatology 2000; 27: 2142—2145.
24. Munro R, Morrison E, McDonald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374—377.
Статины
1. Knopp RH. Drug treatment of lipid disorders. New Engl JMed 1999; 498—511.
2. Vaughan CJ, Gotto AM, Basson CT. The evolvingrole of statins in the management of athroscle-rosis, J Amer Col Cardiol 2000; 35:1—10.
3. Шевченко ОП, Шевченко АО. Статины. Ингибиторы ГМГ-КоА редуктазы. Москва: Реафарм, 2002; 112 с.
4. Chong PH, Seeger JD, Franklin C. Clinically relevant differences the statins: implication for therapeutic selection. Am J Med 2001; 111:390—400.
5. La Roa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A Meta-analy-sis of randomized controlled trials. JAMA 1999; 282: 2340—2346.
6. HMG-Coa reductase inhibitors. Ed. Schmitz G, Torzewski M. Birkhauser Verlag. Basel, Boston, Berkin 2002; 151 p.
7. Salan AM. Expanding indications of statins: implications of the Heart Protecion Study. Exp. Opin Invest Drugs 2003; 12: 509—513.
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425—430.
9. Takemoto M, Liao JK. Pleotropic effects of 3-hydroxy-3methylglutaril coenzyme A reductase inhibitors. Arteriol Thromb Vasc Biol 2001; 21: 1712—1719.
10. Farmer JA. Pleitropic effevts of statins.Curr Atherosclerosis report 2000; 2: 208—217.
11. Munford RS. Statins and the acute-phase response. New Engl J Med 2001; 344: 2016— 2018.
12. Shovman O, Gilburd B, Shoenfeld Y. Anti-inflammatory and immunomodulatory properties of statins. www.rheuma21. com/archives/cut-ting_report_shoenfeld_antiinfl_statins.html.
SHS-OOO4.qxd 21.11.2006 16:56 Page 42
45-
ГЛАВА 14. Новые подходы к профилактике и лечению антифосфолипидного синдрома
13. Palinski W, Tsimikas S. Immunomodula-tory effects of statins: mechanism and potential impact on atherosclerosis. J Amer Soc Nephrol 2002; 13: 1673—1681.
14. McFarline SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87: 1451—1458.
15. Case CC, Ballantyne CM. Starins and inflammatory markers. Curr Aterosclerosis Rep 2002; 4: 42—47.
16. Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr. Atherosclerosis Rep 2003; 5: 33—37.
17. Sposito AC, Chapman MJ. Statin therapy in acute coronaru syndrome. Mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002; 22: 1524—1534.
18. Laufs U, La Fata V, Ptutzky J, Liao JK. Upregulalion of endothelial nitric oxide synthase by HMO CoA reductase inhibitors. Circulation. 1998; 97: 1129—1135.
19. Kureishi Y, Luo Z, Shiojima I, et al. HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis m normocholesterolemic animals. Nat Med 2000; 6:1004—1010.
20. Laufs U, Marra D, Node K, et al. 3-Hydro-xy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho CiTPase-induced down-regulation of p27(Kipl). J Biol Chem I999; 274: 2I926—2I93I.
21. Yang Z, Kozai T, van der Loo B, et al. HMG-CoA reductase inhibition improves endol-helial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Call Cardiol. 2000; 36:1691—1697.
